- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06292169
Pectoralis Minor Release a brak wydania w Republice Południowej Afryki
Randomizowane badanie kontrolne mające na celu ocenę uwolnienia mięśnia piersiowego mniejszego w porównaniu z brakiem uwolnienia mięśnia piersiowego mniejszego po odwrotnej alloplastyce barku
The goal of this clinical trial is to assess if concomitant open pectoralis minor release would improve pain and outcomes after Reverse Shoulder Arthroplasty (RSA). The main questions it aims to answer are:
- whether releasing the pectoralis minor prophylactically could have better pain relief
- whether releasing the pectoralis minor prophylactically could have increased Range of motion (ROM) outcomes
- whether releasing the pectoralis minor prophylactically could have higher final Patient Reported Outcome Measurements (PROMs) Participants will be randomized to either undergo RSA with pectoralis minor release or RSA without pectoralis minor release.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Shoulder arthroplasty has been increasing at exponential rates, particularly due to the rise of reverse shoulder arthroplasty (RSA). Postoperative complications after RSA include infection, instability, hardware component loosening, acromial and scapular spine fractures, neurologic injury, and scapular notching which can all cause pain. However, despite excluding these causes, some patients can have persistent anterior shoulder pain with poor motion.
RSA prostheses work by translating the center of rotation (COR) inferiorly and medially, which increases tension on the deltoid, which is thought to increase the deltoid's mechanical moment arm and thus its ability to abduct and flex the humerus. However, excessive lengthening may be a cause of acromial and scapular spine fractures or neurologic injury. In addition, other structures are tensioned, including the conjoint tendon (short head of the biceps brachii and coracobrachialis) and pec minor (PM). It is unclear if lengthening these muscle-tendon units has functional consequences or whether it can create an intrinsic pathology. It is therefore feasible that muscle lengthening could create tendinitis, which could lead to persistent anterior shoulder pain after RSA. In addition, excessive tension or over-activity in the PM is also known to be a cause of altered scapula biomechanics.
Good scapula biomechanics after RSA are critical to preserving an impingement-free range of motion, which is important in maximizing postoperative outcomes, implant longevity, and preventing component loosening and instability. However, it is known from the non-arthroplasty population that during repetitive movements with scapular protraction, a hyperactive or spasming PM shortens and develops contracture, leading to protracted resting scapular position and altered scapular contribution to shoulder range of motion.1 This causes altered scapular kinematics, or dyskinesia, and alters scapular accommodation to shoulder motion, a well-known feature in various shoulder pathologies. This can be a major problem after RSA when scapula accommodation is critical to ROM and function.
Due to the expendability of the pectoralis minor, its release would cause minimal functional detriment in non-pathological cases, but in cases of overactivity, release could markedly improve scapula biomechanics. This can be performed open or arthroscopically, but the concomitant open release would be straight-forward at the time of the index surgery through the same incision
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Emory Clinic
-
Atlanta, Georgia, Stany Zjednoczone, 30329
- Emory Healthcare Orthopaedics and Spine Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- All patients undergoing surgery for reverse total shoulder arthroplasty
- Patients willing and able to provide informed consent
Exclusion Criteria:
- Revision arthroplasty
- Reverse shoulder arthroplasty for proximal humerus fractures
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: RSA z niewielkim uwolnieniem mięśnia piersiowego
|
The pectoralis minor is a muscle on the anterior chest wall attaching to the coracoid process. In the group undergoing pectoralis minor release, through the same deltopectoral incision that will not be extended or different as compared to the RSA only group, the pec minor will be exposed on the medial aspect of the coracoid at the upper part of the incision. It will be cut from its insertion on the coracoid while being careful to protect any neurovascular structures. RSA is the current Standard of Care (SOC) |
|
Aktywny komparator: RSA bez niewielkiego uwolnienia mięśnia piersiowego
|
RSA is the current Standard of Care (SOC) |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Visual analog Scale (VAS) pain scores
Ramy czasowe: Baseline, 6 months
|
The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). Study participants will be asked to rate their current level of pain by placing a mark on the line |
Baseline, 6 months
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Visual analog Scale (VAS) pain scores
Ramy czasowe: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). Study participants will be asked to rate their current level of pain by placing a mark on the line |
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
|
American Shoulder and Elbow Score (ASES)
Ramy czasowe: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
The ASES is a 100-point scale that consists of two dimensions: pain and activities of daily living. There is one pain scale worth 50 points and ten activities of daily living worth 50 points. |
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
|
Subjective Shoulder Value (SSV)
Ramy czasowe: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
Subjective Shoulder Value is study participant's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% |
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
|
Change in Range of motion (ROM)
Ramy czasowe: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
ROM is calculated in terms of angles. Lower number suggests restricted motion. |
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
|
Change in Scapulohumeral Rhythm (SHR) on Digital Dynamic Radiography (DDR)
Ramy czasowe: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
SHR is the ratio of humeral abduction over the change in scapula upward rotation during humeral abduction. This SHR will be captured on Digital Dynamic Radiography (DDR) and reported as a change in SHR before and after the interventions. |
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
|
Number of complications
Ramy czasowe: 1 year
|
Number of complications post intervention would be measured. |
1 year
|
|
Number of reoperations
Ramy czasowe: 1 year
|
Number of reoperations following intervention would be measured. |
1 year
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Eric Wagner, MD, Emory University
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- STUDY00007201
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .